The US Food and Drug Administration (FDA) has granted Fast Track designation for Biohaven’s new anti-myostatin adnectin, taldefgrobep alfa, to treat spinal muscular atrophy (SMA).
The new myostatin-targeting biologic investigational agent has been designed for specific binding to myostatin (GDF-8) to reduce overall levels of myostatin.
It also works as a receptor antagonist to block myostatin signalling in skeletal muscles.
Taldefgrobep is a complete human anti-myostatin recombinant protein that is developed for lowering free myostatin.
Biohaven stated that taldefgrobep can also be used along with disease-modifying therapies for improving muscle function by blocking the activity of myostatin.
Read the full press release here
